Evidence map›Paper›PMID 30443916›Full record

Observational studyClinical cardiology2019

Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry.

Xavier Rossello, Héctor Bueno, Stuart J Pocock, Frans Van de Werf, Nicolas Danchin, Lieven Annemans, Jesús Medina, Uwe Zeymer

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01171404 (Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01171404 completednot on this map

Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients

TypeobservationalSponsorAstraZenecaRan2010 to 2013Enrolled10,568ConditionsACS, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines.European heart journal. Quality of care & clinical outcomes · 2023
    Trial
  4. Article
  5. Article
  6. Observational
  7. Plasma concentration of TMAO is an independent predictor of adverse outcomes in patients after acute myocardial infarction.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Observational
  14. Observational
  15. Acute myocardial infarction with high Killip class: do geographic differences matter?European heart journal. Acute cardiovascular care · 2021
    Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xavier RosselloCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID https://orcid.org/0000-0001-6783-8463
Héctor BuenoCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Stuart J PocockLondon School of Hygiene and Tropical Medicine, London, UK.
Frans Van de WerfDepartment of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Nicolas DanchinHôpital Européen Georges Pompidou, René Descartes University, Paris, France.
Lieven AnnemansInteruniversity Centre for Health Economics Research (I-CHER), Ghent University, Ghent, Belgium.
Jesús MedinaGlobal Medical Affairs, CardioVascular, Renal and Metabolism, AstraZeneca, Madrid, Spain.
Uwe ZeymerKlinikum Ludwigshafen and Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.

Funding

AstraZeneca
6 · The paper itself

Abstract

backgroundPatients discharged after an acute coronary syndrome (ACS) have substantial risk of recurrent ischemic events or dying. HYPOTHESIS: A difference may exist in risk predictors for all-cause mortality and ischemic events between year 1 and 2 of follow-up post-ACS.

methodsEPICOR (NCT01171404) was a prospective, international, real-world cohort study of consecutive patients hospitalized for ACS within 24 hours of symptom onset and surviving to discharge. Total of 10 568 patients were enrolled (555 hospitals; 20 countries) and followed-up for 2 years. From these, 4943 were admitted with ST-elevation myocardial infarction (STEMI) and 5625 with non-ST-elevation ACS (NSTE-ACS). Potential baseline predictors of major adverse cardiac and cerebrovascular events (MACCE; death, non-fatal myocardial infarction [MI], non-fatal stroke) were evaluated in year 1 and 2 post-discharge.

resultsMACCE incidence per 100 person-years at risk within and after 1 year was 5.3 vs 3.6, primarily death (4.1 vs 2.3), with no significant differences for MI or stroke. Older age, lack of coronary revascularization, raised creatinine, low hemoglobin, previous cardiac disease, previous chronic obstructive pulmonary disease, raised glucose, male sex, and geographic region were risk factors for MACCE in both year 1 and 2. By contrast, low ejection fraction, poorer quality of life, low body mass index (BMI) <20 kg/m

conclusionWe observed continuous MACCE risk during 2 years of follow-up after discharge for ACS, with greater mortality within the first year. Specific predictors at discharge for events after 1 year could not be identified.

Indexed as

RegistriesAcute Coronary SyndromeAgedCause of DeathEuropeFemaleFollow-Up StudiesHumansIncidenceLatin AmericaMaleMiddle AgedMyocardial InfarctionPopulation SurveillancePrognosisProspective Studiesacute coronary syndromehospital dischargemortalityprognostic modelrisk predictor

Identifiers

PMID30443916
PMCPMC6436503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.